JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 243 filers reported holding JUNO THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is 0.72 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $11,907,000 | +34.1% | 260,490 | +31.6% | 0.01% | +22.2% |
| Q3 2017 | $8,879,000 | +41.4% | 197,942 | -5.8% | 0.01% | +50.0% |
| Q2 2017 | $6,278,000 | -7.4% | 210,051 | -31.3% | 0.01% | 0.0% |
| Q1 2017 | $6,781,000 | +86.6% | 305,593 | +58.5% | 0.01% | +50.0% |
| Q4 2016 | $3,634,000 | -35.3% | 192,806 | +3.0% | 0.00% | -20.0% |
| Q3 2016 | $5,621,000 | +18.0% | 187,262 | +51.1% | 0.01% | 0.0% |
| Q2 2016 | $4,762,000 | -9.5% | 123,916 | -10.3% | 0.01% | -16.7% |
| Q1 2016 | $5,261,000 | +219.2% | 138,112 | +268.5% | 0.01% | +200.0% |
| Q4 2015 | $1,648,000 | -45.0% | 37,483 | -33.2% | 0.00% | -33.3% |
| Q2 2015 | $2,995,000 | – | 56,151 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 2,168,601 | $65,080,000 | 86.12% |
| Crestline Management, LP | 17,348,799 | $520,637,000 | 66.02% |
| Omega Fund Management, LLC | 1,229,512 | $36,898,000 | 28.17% |
| SIB LLC | 100,000 | $3,001,000 | 2.42% |
| Clarius Group, LLC | 117,896 | $3,538,000 | 1.65% |
| BB BIOTECH AG | 1,405,000 | $42,164,000 | 1.48% |
| Duquesne Family Office | 493,000 | $14,795,000 | 1.31% |
| First Washington CORP | 65,320 | $1,960,000 | 1.10% |
| PFM Health Sciences, LP | 1,124,285 | $33,740,000 | 0.99% |
| Partner Investment Management, L.P. | 18,376 | $551,000 | 0.82% |